[EN] SMALL MOLECULE COMPOUNDS TO SUPPORT HEALTHY HUMAN AGING<br/>[FR] COMPOSÉS À PETITES MOLÉCULES POUR FAVORISER UN VIEILLISSEMENT HUMAIN SAIN
申请人:CARDAX PHARMA INC
公开号:WO2018183353A1
公开(公告)日:2018-10-04
Disclosed herein are methods of activating expression of the FOXO3 gene in a subject comprising administering to a subject small molecule compound (such as astaxanthin and/or one or more astaxanthin derivatives), or pharmaceutically acceptable salts thereof, in an amount sufficient to at least partially increase the amount of FoxO3 expressed in the subject.
USES OF TRITERPENOID MIXTURE FOR TREATING MULTIPLE SCLEROSIS
申请人:Trineo Biotechnology Co. Ltd
公开号:EP3509602A1
公开(公告)日:2019-07-17
JP2005035898A
申请人:——
公开号:JP2005035898A
公开(公告)日:2005-02-10
[EN] USES OF TRITERPENOID MIXTURE FOR TREATING MULTIPLE SCLEROSIS<br/>[FR] UTILISATIONS D'UN MÉLANGE DE TRITERPÉNOÏDES POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES
申请人:TRINEO BIOTECHNOLOGY CO LTD
公开号:WO2018082034A1
公开(公告)日:2018-05-11
Disclosed herein is a novel use of a triterpenoid mixture for the treatment of multiple sclerosis (MS). The triterpenoid mixture consists of, ganoderic acid A (GAA), ganoderic acid B (GAB), ganoderic acid C (GAC), ganoderic acid C5 (GAC5), ganoderic acid C6 (GAC6), ganoderic acid D (GAD), ganoderic acid E (GAE), ganoderic acid G (GAG), and ganoderenic acid D. The triterpenoid mixture may be administered to a subject suffering from MS in a dose of about 1 to 10 mg/Kg to ameliorate or alleviate symptoms associated with MS.